glp-1 obesity drug news october 2025 A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio 1 in 10 Americans Has
Description
The use of incretin mimetics for people with type 2 diabetes and CKD was also considered not cost-effective, despite evidence from the semaglutide FLOW trial
Experts do not recommend using these medicines for depression or bipolar disorder outside approved medical indications or clinical trials
Lancet 402 , 504505 (2023)
Facts & Comparisons eAnswers
Diabetes Metabolism Research Reviews
If an SNP did not meet the Affymetrix prescribed QC thresholds in a given batch, it was set to missing in all individuals from that batch
